Information  X 
Enter a valid email address

Creo Medical Group (CREO)

  Print      Mail a friend

Friday 10 May, 2019

Creo Medical Group

Mello 2019

RNS Number : 5235Y
Creo Medical Group PLC
10 May 2019
 

Creo Medical Group plc

("Creo" or the "Company")

 

Mello 2019

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces it will be exhibiting at Mello 2019 on Thursday 16 May at the Clayton Hotel Chiswick, London.

 

Members of Creo's management team will be at a stand in the Exhibitor Room throughout the day and Chris Hancock, CTO, will be presenting at 9.15am in the PI World Room.

 

For further information, please visit the event website at: https://melloevents.com/event/

 

The presentation will be available on the Company website shortly after the event here:

http://investors.creomedical.com/investors/reports-and-presentations/2019 

 

If you are interested in attending the event and would like information on how to register, please contact Walbrook PR at [email protected]

 

No new material information will be disclosed at the event.

 

 

Creo Medical Group plc

 

Richard Rees (CFO)

+44 (0)129 160 6005

 

 

Cenkos Securities

+44 (0)20 7397 8900

Stephen Keys / Mark Connelly (NOMAD)

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Helen Cresswell

Mob: +44 (0)7841 917 679

 

About Creo Medical

 

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. Creo's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radio frequency energy (for precise localised cutting) and microwave energy (for controlled coagulation). This technology provides clinicians with flexible, accurate and controlled surgical solutions.

 

Creo's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which Creo has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  Creo intends to further develop the CROMA Advanced Energy platform for use on flexible and rigid endoscopic platforms for precise resection, dissection, haemostasis and ablation. Creo believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option of treatment.

 

For more information about Creo Medical please see our website, investors.creomedical.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAUGUGUAUPBGUB

a d v e r t i s e m e n t